News & Events

and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. At the 2026 Annual Meeting (as defined below) of bioAffinity Technologies, Inc. (the “Company”), stockholders approved an amendment to the Company’s 2024 Equity Incentive Compensation Plan (the “2024 Plan”) to increase the number of shares of common stock, par value $0.007 per share (the “Common Stock”), reserved for issuance thereunder to 1,000,00…

and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 5, 2026, Robert Anderson and Roby Joyce informed the Board of Directors (the “Board”) of bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), of their decisions not to stand for re-election to the Board upon expiration of their current terms, which expire at the Company’s 2026 Annual Meeting of Stockholders, currently sc…

and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this

Entry into a Material Definitive Agreement. Registered Direct Offering On October 8, 2025, bioAffinity Technologies, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue to the Purchasers in a registered direct offering (the “Offering”), 720,000 shares (the “Shares”) of the Company’s common stock, par value $0.007 per share (the “Common Stock”). The Offering c…

Entry into a Material Definitive Agreement. On September 29, 2025, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), consummated a best efforts public offering (the “Offering”) of an aggregate of (i) 1,047,694 shares (the “Shares”) of common stock, par value $0.007 per share (the “Common Stock”) and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 874,067 shares of Common Stock (“Pre-Funded Warrants Shares”) in lieu of Shares. Each Share was sold at…

Other Events The Company issued a press release announcing the pricing of the Offering on September 29, 2025. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein. The Company issued a press release announcing the closing of the Offering on September 30, 2025. A copy of the press release is filed herewith as Exhibit 99.2 and is incorporated by reference herein. As of the date of this Current Report on Form 8-K, after the closing of the Offering…

Material Modification to Rights of Security Holders. To the extent required by

Entry into a Material Definitive Agreement On September 2, 2025, bioAffinity Technologies, Inc, (the “Company”) and the holders of the warrants issued by the Company on May 7, 2025 (the “May 2025 Warrants”) and the warrants issued by the Company on August 13, 2025 (the “August 2025 Warrants”) agreed, effective as of August 12, 2025, to amend the Floor Price (as such term is defined in each of the May 2025 Warrants and the August 2025 Warrants) so as to increase it from $0.10 to $0.15. As a re…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 12, 2025, the board of directors (the “Board”) of bioAffinity, Inc. (the “Company”) appointed Roberto Rios, CPA and John J. Oppenheimer, M.D. as members of the Board, each with an initial term expiring at the Company’s 2026 annual meeting of stockholders . Neither Mr. Rios nor Dr. Oppenheimer was selected as a director pursuant to any arr…

Other Events. On August 13, 2025, the Company issued a press release announcing the pricing of the Private Placement and Warrant Inducement. On August 14, 2025, the Company issued a press release announcing the closing of the Private Placement and Warrant Inducement. Copies of the press releases are furnished as Exhibit 99.1 and Exhibit 99.2, respectively to this Form 8-K. - 4 -

The Series B Preferred Stock, Warrants, and New Warrants are being issued without registration under the Securities Act, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.

and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this

Entry into a Material Definitive Agreement Private Placement Transaction On August 13, 2025, bioAffinity Technologies, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional and accredited investors (“the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Private Placement”), (i) 990 shares of the Company’s newly designated Series B Convertible Preferred Stock, with a par value $0…